ValuEngine Downgrades Tabula Rasa HealthCare (TRHC) to Hold

Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

Several other brokerages also recently commented on TRHC. Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 22nd. BidaskClub upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a report on Friday, March 22nd. First Analysis upgraded shares of Tabula Rasa HealthCare from an “outperform” rating to a “strong-buy” rating and set a $58.33 target price for the company in a report on Monday, March 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a report on Thursday, February 28th. Finally, Oppenheimer lowered their target price on shares of Tabula Rasa HealthCare from $97.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, March 6th. Five investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $80.53.

Shares of TRHC stock traded down $2.55 on Monday, hitting $44.24. The stock had a trading volume of 379,700 shares, compared to its average volume of 390,814. The company has a market cap of $1.05 billion, a P/E ratio of 130.12 and a beta of 1.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 0.79. Tabula Rasa HealthCare has a 12-month low of $43.31 and a 12-month high of $91.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). The company had revenue of $60.96 million during the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%.

In related news, CEO Calvin H. Knowlton sold 8,270 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $48.50, for a total transaction of $388,000.00. The disclosure for this sale can be found here. Insiders have sold 48,270 shares of company stock valued at $2,645,294 in the last 90 days. 14.00% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of TRHC. First Mercantile Trust Co. purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $39,000. TCI Wealth Advisors Inc. increased its holdings in Tabula Rasa HealthCare by 1,600.0% during the fourth quarter. TCI Wealth Advisors Inc. now owns 850 shares of the company’s stock worth $54,000 after buying an additional 800 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $64,000. Neuburgh Advisers LLC increased its holdings in Tabula Rasa HealthCare by 34.9% during the first quarter. Neuburgh Advisers LLC now owns 2,288 shares of the company’s stock worth $129,000 after buying an additional 592 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $135,000. Institutional investors and hedge funds own 78.60% of the company’s stock.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Read More: How can you know how many shares are floating?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.